Wednesday, July 8, 2026

pharma · Chronic Lymphocytic Leukemia · Relapsing Multiple Sclerosis · TGTX

TG THERAPEUTICS

TG THERAPEUTICS clinical programs — 15 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US HQ
2011 Founded
521 Employees
Public company Type
TGTX · NYSE Ticker
Company details
Status
Public
HQ
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US
Founded
2011
Employees
521
Programs
39
Drugs
23
Patents
7
Intelligence · Clinical Programs

TG THERAPEUTICS projects

15 ClinicalTrials.gov programs sponsored by TG THERAPEUTICS.

TG THERAPEUTICS has 15 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Azercabtagene zapreleucel (azer-cel)

    TG THERAPEUTICS, INC.

    B-cell Mediated Autoimmune Disorders

    phase 1 small molecule active

    1 trial
  2. Cosibelimab

    TG THERAPEUTICS, INC.

    B-cell Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial
  3. NM1F Injection

    TG THERAPEUTICS, INC.

    Ovarian Cancer

    phase 1 small molecule active

    1 trial
  4. TG-1701

    TG THERAPEUTICS, INC.

    Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial
  5. TG-1801

    TG THERAPEUTICS, INC.

    B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial
  6. TG-1801

    TG THERAPEUTICS, INC.

    CLL

    phase 1 mab terminated

    1 trial
  7. TG1101-RMS-SC101

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis, Myasthenia Gravis

    phase 1 small molecule active

    1 trial
  8. TGI-5

    TG THERAPEUTICS, INC.

    CRC (Colorectal Cancer)

    phase 1 small molecule active

    1 trial
  9. TGI-6 Injection

    TG THERAPEUTICS, INC.

    Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial
  10. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 1 small molecule completed

    1 trial
  11. TGR-1202

    TG THERAPEUTICS, INC.

    Non-Hodgkin's Lymphoma

    phase 1 small molecule completed

    1 trial
  12. TGR-1202

    TG THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial
  13. TGR-1202 + Obinutuzumab + Chlorambucil

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial
  14. TGR-1202 + brentuximab vedotin

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 1 small molecule completed

    1 trial
  15. Ublituximab + TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does TG THERAPEUTICS have?

15 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.